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The emergence of ablative therapies has revolutionized the treatment of inoperable solid
tumors. Cryoablation stands out for its uniqueness of operation based on hypothermia,
and for its ability to unleash the native tumor antigens, resulting in the generation of anti-
tumor immune responses. It is not clearly understood how alterations in the rate of freeze
impact the immune response outcomes. In this study, we tested fast freeze and slow
freeze rates for their locoregional effectiveness and their ability to elicit immune responses
in a B16F10 mouse model of melanoma. Tumor bearing mice treated with fast freeze
protocol survived better than the ones treated with slow freeze protocol. Fast freeze
resulted in a higher magnitude of CD4+ and CD8+ T-cell responses, and a significantly
extended survival post re-challenge. Thus, fast freeze rate should be applied in any future
studies employing cryoablation as an in vivo vaccination tool in conjunction with
targeted immunotherapies.
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Cryoablation is increasingly applied in the clinics for the local management of tumors, including
malignancies of kidney, lung, soft tissues and bone cancers. Cryoablation proved its ability to
effectively eradicate small tumors inoperable by surgery. In contrast to surgery which totally
removes tumor tissues, in situ ablation of tumors also releases tumor antigens into systemic
circulation, eliciting immune responses against tumor-specific and tumor-associated antigens (1).
Cryoablation results in a higher magnitude of post-ablative immunogenic responses as
compared to radiofrequency ablation or laser induced thermotherapy, which could be partly due
to the preservation of tumor antigenic structures that are otherwise denatured in hyperthermic
ablation procedures (2). The immune responses post-ablation were suggested as the underlying
mechanism for the spontaneous regression of metastases occasionally observed post cryoablation of
primary tumors (3–5). This immunogenic potential along with its minimal invasiveness,
repeatability, and relatively painless properties makes cryoablation an attractive option to beorg June 2021 | Volume 12 | Article 6951501
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metastatic disease, in order to achieve improved systemic anti-
tumor immune responses. Indeed, co-application of cryoablation
with TLR agonists, adoptive immune cell therapies and
checkpoint inhibitors have been shown to be beneficial in
various tumor mouse models and patients with cancer (6–10).
Rate of freeze is a crucial factor that dictates the effectiveness
of cryoablation (11). Fast and slow freezing rates have long been
suggested to vary in their biophysical processes of inducing cell
injury (12). Fast freeze rate is employed for the locoregional
treatment of solid tumors in the clinic. Nevertheless, the effect of
freeze rate on the mode of tissue death (i.e. apoptosis vs necrosis)
and its impact on the subsequent immune responses, remains
largely elusive to date. Our study aims to address these aspects,
which will be pivotal in the context of employing cryoablation as
an in vivo vaccination tool for cryo-immunotherapies. To
increase the translational relevance of our study, we used a
clinical cryoablation system, and compared fast and slow freeze
rates in their locoregional effectiveness on tumor growth and
viability, and their ability to generate immune responses in a
B16F10 mouse model of melanoma. We performed an extensive
immune cell phenotyping by flow cytometry of tumors, tumor
draining and non-draining lymph nodes. Our results
demonstrate significant changes in the overall frequencies of
CD4+ and CD8+ T-cell subsets in the lymph nodes following
cryoablation, and are more pronounced in the fast freeze mode of
ablation. Re-challenge experiments resulted in an extended
survival of mice treated with fast freeze protocol (in
comparison to non-treated controls), indicative of tumor-
specific immune responses elicited post cryoablation. Taken
together, our data suggests an advantage of fast freeze over
slow freeze rate in the locoregional tumor control and the
generation of immune responses.MATERIALS AND METHODS
Tumor Cell Line
B16F10 melanoma cells (Ludwig Institute for Cancer Research
(LICR), Lausanne) were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) (31966-021, gibco), supplemented with 10% fetal
bovine serum (FBS) (10270, gibco) and 1% penicillin-streptomycin
(15140-122, gibco), maintained at 5% CO2 and 37°C.
Animal Model
C57BL/6JOlaHsd female mice were purchased from Envigo
(Gannat, France). Animals were maintained in specific
pathogen-free conditions. Experiments were performed as per
the institutional guidelines, approved by Service de la
Consommation et des Affaires Vétérinaires, Vaud, Switzerland.
Animals were allowed to acclimatize for at least one week prior
the start of experiments. Mice were given food and water
ad libitum. 8-10 week old mice were shaved on the flank, and
transplanted subcutaneously with 5 x 106 B16F10 cells re-
suspended in 100µl phosphate buffer saline (PBS). The day of
transplant is considered as day 1 time point. For re-challenge
experiments post cryoablation, mice received 5 x 106 B16F10Frontiers in Immunology | www.frontiersin.org 2cells in a similar manner on the contralateral flank. Tumor
growth was measured by electronic vernier calipers, and the
volume was calculated by the formula: (width2 x length)/2.
Experimental Design
Mice with tumors were randomized into 3 groups: (a) non-treated
group, (b) slow-freeze group, and (c) fast-freeze group. Tumor
growth was measured in all animals on the day of cryoablation
(groups were well balanced with no statistically significant
differences in tumor size at baseline), followed by every 2 days
post ablation, alongside the non-treated controls. Mice that
developed tumors ≥1000mm3 volume or showed severe
impairment were sacrificed as per the local regulations. Surviving
mice that were free of tumors were subjected to re-challenge
experiments 2 months post primary B16F10 transplant. For
analyses by flow cytometry and immunohistochemistry, animals
were randomly sacrificed at day 3-4 or 7-8 post-cryoablation.
For the analysis of plasma cytokines, blood was extracted
from the tail vein on 2 days prior cryoablation, followed by 3
days or 8 days post cryoablation. Blood was collected in
anticoagulant coated tubes, centrifuged, and the supernatant
plasma was collected and frozen at -800C for further cytokine
analyses. Tumor necrosis factor-a (TNF-a), interleukin (IL)-1a,
IL-1b, IL-12p70, IL-10, IL-6, IL-17a, IFN-b, IFN-g, IL-23, IL-27,
monocyte chemoattractant protein-1, and granulocyte monocyte
colony stimulating factor were measured by Legendplex kit as
per the manufacturer’s instructions (740446, Biolegend).
Cryoablation
Tumors were cryoablated at day 7-9 post B16F10 cell transplant.
Mice were anesthetized by 2-2.5% isoflurane inhalation. The skin
above the tumor and its surrounding area was shaven,
disinfected with 70% ethanol. An incision was created on the
skin adjacent to the tumor in order to expose the tumor for
cryoablation. To increase the translational value of gathered data,
we utilized a cryomachine used in the clinic (Visual ICE System
BTG, Boston Scientific). The cryoprobe was inserted into the
tumor followed by a freeze-thaw process. Freeze step involved
the release of high-pressure Argon gas through the needle into
the tumor until the tumor was completely frozen (macroscopic
ice ball encapsulates the tumor). Thaw step involved allowing the
tumor to passively defrost and return to its previous state. All the
cryoablations involved two freeze-thaw cycles. Fast freeze
indicates 100% freeze intensity (uninterrupted Argon flow) as
opposed to slow freeze that represents 5% freeze intensity (i.e.,
Argon is pumped for 0.5 seconds in every 10 second time
period). Surgical wounds were closed with non-absorbable
sutures. Paracetamol was given to mice in drinking water
(2mg/ml) as an analgesic for a period of one week
post-cryoablation.
Flow Cytometry of Tumors and
Lymph Nodes
Tumor tissues (ablated and non-ablated) were digested by mouse
tumor dissociation kit (130-096-730, Miltenyi Biotec) as per the
manufacturer’s instructions in a gentleMACS™ octodissociator
(130-096-427, Miltenyi Biotec), under 37C_m_TDK_2 program.June 2021 | Volume 12 | Article 695150
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RBC lysis buffer (00-4333-57, Thermo Fisher Scientific). As a
final step, tumor cells were re-suspended in PBS and filtered
through 70µm MACS smart strainers (130-110-916, Miltenyi
Biotec) to obtain single cell suspensions. Tumor draining and
non-draining (contralateral) inguinal lymph nodes were mashed
in PBS and filtered through a 60µm nylon mesh to obtain single
cell suspensions. Tumor and lymph node cells were incubated
with Fc block (LICR) for 15-20min at 4°C prior staining with
monoclonal antibodies.
Tumor cells were stained for cell surface antigens with the
following monoclonal antibodies: CD45-APC (clone: M1/89,
LICR), CD11b-pacific blue (M1/70, LICR), CD11c-PerCP-
Cy5.5 (N418, eBioscience™), MHC-II-BV785 (M5/114.15.2,
B ioLegend) , S i g l e c -F - superb r i gh t600 (1RNM44N;
eBioscience™) F4/80-APC-eFluor780 (BM8, eBioscience™),
Ly6C-BV711 (HK1.4, Biolegend), Ly6G-BUV395 (1A8, BD
Biosciences), CD80-PE-Cy7 (16-10A1, BioLegend). Cells from
lymph nodes were stained for cell surface antigens with the
following monoclonal antibodies: CD3-BUV737 (145-2C11, BD
Biosciences) CD4-BUV395 (RM4-5, BD Biosciences), CD8-
APC-eFluor780 (53-6-7, eBioscience™), CD11b-pacific blue
(M1 /70 , L ICR ) , CD62 -L -P e rCP -Cy5 . 5 (MEL-14 ,
eBioscience™), CD44-BV605 (IM7, Biolegend), MHC-II-
BV785 (M5/114.15.2, BioLegend), CD11c-APC (N418,
eBioscience™) , CD279/PD-1-Super Bright645 (J43,
eBioscience™)s, CD69-BV711 (H1.2F3, BioLegend), CD80-PE-
Cy7 (16-10A1, BioLegend). Intracellular staining was performed
with Ki-67-PE-Dazzle594 (16A8, BioLegend) and Foxp3-PE
(FJK-16s, eBioscience™) antibodies. Tumor and lymph node
cells were subjected to cell surface antigen staining for 30-40
minutes at 4°C. For the exclusion of non-viable cells, LIVE/
DEAD™ fixable aqua dead cell stain kit (L34966, Thermo Fisher
Scientific) was used. Cells were then fixed and permeabilized
with Foxp3 transcription factor staining buffer set (00-5223-56,
Thermo Fisher Scientific) as per the manufacturer’s instructions.
Lymph node cells were further subjected to Ki-67 and Foxp3
intracellular staining for 30-40 minutes at room temperature.
Cells were washed and re-suspended in PBS, and filtered
through 60µm nylon mesh for acquisition by flow cytometry.
Sample acquisition was performed on BD Fortessa or
CytoFLEX LX analyser, and the data was analyzed using
FlowJo software (v10.2).
Elispot
Spleens were isolated from mice at 13-14 days post B16F10 cell
transplant or 7-8 days post-cryoablation. Spleens were mashed,
subjected to RBC lysis, and single cell suspensions were prepared
in a T-cell media comprising RPMI media (61870-010, gibco)
with 10% FBS, 1% pencillin-streptomycin, 1% minimal essential
media (11140-035, gibco), 1% sodium pyruvate (11360-039,
gibco), 1%HEPES (15630-056, gibco) and 0.1% beta-
mercapitoethanol (11140-035, gibco). Splenocytes were
cultured at 5% CO2 and 37°C. At day 3 and 6 of culture,
300units/ml of IL-2 (212-12, peprotech) was added to
stimulate the proliferation of T-cells. On day 8, cultured cells
were harvested and subjected to CD8+ T-cell enrichment by CD8Frontiers in Immunology | www.frontiersin.org 3T-cell isolation kit (130-104-075, Miltenyi Biotec). CD8+ T-cells
were seeded into 96-well Interferon-g (IFN-g) elispot plates at
200,000 cells/well. Murine trp-2 peptide (SVYDFFVWL, LICR)
of 0.2µg was added to each well as a tumor antigen peptide. For
the control wells, ovarian ID-8 tumor derived peptide
(YACENGQTDV, LICR) was added as an irrelevant peptide.
Freshly isolated and irradiated splenocytes of 10,000 cells/well
were added as a source of antigen presenting cells. Elispot assay




For tetramer staining to detect the presence of antigen
specific CD8+T-cells, single cell suspensions of 1-5million
cells from spleen were subjected to Fc blocking, and stained
at room temperature with Trp-2-BV421 (TB-5004-4,
MBL International) and gp-100-PE (TB-M505-1, MBL
International) tetramers for 30min. The cells were then stained
with CD19-APC/Cy7 (6D5, Biolegend), CD4-BUV395 and CD8-
FITC (KT15, Invitrogen) antibodies, along with LIVE/DEAD™
fixable aqua dye at 4°C for 30min. Cells were then fixed with
Foxp3 transcription factor staining buffer set prior flow
cytometry analysis.
For the detection of intracellular cytokines, 1-5million cells
obtained from spleen were subjected to in vitro stimulation with
50 ng/ml of phorbol 12-myristate 13-acetate (P8139, Sigma-
Aldrich) and 750 ng/ml ionomycin (407952, Sigma-Aldrich) for
6 hours at 37°C, 5% CO2 in the T-cell media (as described for
elispot). 1X Brefeldin-A (420601, BioLegend) was added in the
last 4 hours to prevent the secretion of cytokines. After 6 hours,
cells were subjected to Fc blocking, followed by staining with
CD3-BUV737, CD8-APC-eFluor780, CD4-BUV395 antibodies
and LIVE/DEAD™ fixable aqua dye at 4°C for 30min. Cells were
then fixed and permeabilized with Foxp3 transcription factor
staining buffer set, intracellularly stained with IFN-g-PE
(XMG1.2, eBioscience™) and TNF-a-APC (MP6-XT22,
eBioscience™) antibodies. Isotype control staining was done
with IgG1 kappa antibody (eBRG1, eBioscience™). Sample
processing post staining, and data acquisition by flow
cytometry was performed as mentioned above.
Histology and Immunohistochemistry
Hematoxylin and eosin (H&E) and caspase-3 staining was
performed on 5µm sections of formalin-fixed paraffin-
embedded tumor tissues. Sections were briefly incubated in
xylene and a gradient of alcohol solutions (100%, 95%, 80%)
followed by H20 for deparaffinization. They were then stained
with hematoxylin for 4 minutes followed by washing with H20
and incubation in 1% acid-alcohol (1% of 37%HCl, and 70%
alcohol) for 3 seconds. The sections were washed again and
subjected to eosin staining for 30 seconds, washed, dehydrated
and mounted for image analysis. For cleaved caspase-3 staining,
sections were prior subjected to melanin removal by treatment
with potassium permanganate and oxalic acid (13), followed by
staining as per the manufacturer’s instructions (#9661,
Cell Signaling).June 2021 | Volume 12 | Article 695150
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quantification of tumor necrosis. Pathologic tumor necrosis
(H&E) and apoptosis (cleaved caspase-3 positive cells) were
quantified in representative tumor slides by experienced liver
pathologists (J.D. & C.S.) who were blinded to all data.
Tumor slides were analyzed by microscopy. The total surface
area was quantified and determination of percentage of tumor
necrosis was assessed as a percentage of the total area of the
tumor present within the histological sections. Tumor necrosis
was assessed by increments of 10%, blindly and independently by
two pathologists, at different time points. If discordant, cases
were reviewed and quantified as a mean value.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism
software (v7.03, La Jolla, CA). Data are represented as mean ±
standard deviation. Statistical comparisons of the data sets were
performed using the Mann-Whitney U test. Kaplan-Meier
survival curves were compared by log-rank (Mantel-Cox) test. A
two-tailed P-value of < 0.05 was considered statistically significant.RESULTS
Rate of Freeze Influences Locoregional
Tumor Growth and Survival
We evaluated the effectiveness of fast and slow freeze rates in
their ability to locally ablate the tumor in a B16F10 model of
melanoma. Cryoablation by either protocols resulted in a
significant delay of tumor growth and enhancement of survival
over non-treated controls (Figure 1 and Supplementary
Figure 1). Furthermore, mice treated with fast freeze protocol
resulted in an improved survival over slow freeze protocol; 44%
of mice were alive and tumor-free at the end of the 2month
follow-up period when treated with the fast freeze protocol vs
17% when treated with the slow freeze protocol (P-value <0.05;
Figure 1). Overall, these results demonstrate that fast freeze
outperforms slow freeze in its ability to locoregionally treat
melanoma tumors.
Rate of Freeze Influences Tumor Necrosis
but Does Not Induce Apoptosis
Survival outcomes obtained from differential freeze rates
prompted us to determine the extent of necrosis induced in
the tumors, examined at 8 days post-cryoablation by H&E
staining. Apart from the spontaneous necrosis observed in the
non-treated mice, we observed a significantly increased ablation-
induced necrosis, with markedly higher necrosis in fast freeze as
compared to slow freeze groups (Figure 2), corroborating the
data obtained from survival experiments. Treatment-induced
apoptosis, as measured by cleaved caspase-3 staining, was not
observed at the periphery of the ablated zone (Supplementary
Figure 2). Interestingly, cleaved caspase-3 positive cells were
present at the limiting plate zone between spontaneous tumor
necrosis and viable tissue in particular in the non-treated tumors
(Supplementary Figure 2). Taken together, these results showFrontiers in Immunology | www.frontiersin.org 4that apoptosis may be observed at the rim of spontaneous
necrosis in melanoma tumors, and that cryoablation besides
causing tumor necrosis, did not induce apoptosis at the
periphery of the ablated zone.
Cryoablation Modulates the Immune
Landscape in TDLN and TNDLN
We next tested the ability of slow and fast freeze protocols to
initiate local and systemic immune responses, by performing
extensive flow cytometry analyses of various immune cell subsets
in lymph nodes and tumors (Supplementary Tables 1–6). T-cell
populations in the lymph nodes were characterized by flow
cytometry based on the expression of CD4, CD8, CD62L,
CD44, Foxp3 and Ki67 markers (Figure 3A). In the local
tumor draining lymph node (TDLN), at day 3-4 post
cryoablation, increased frequencies of CD8+ central memory
T-cells and Foxp3+ CD4+ regulatory T-cells (Tregs) were
observed only in the fast freeze group as compared to non-
treated controls. In addition, central memory subset of CD8+ T-
cells were also significantly higher in fast freeze group as
compared to slow freeze group (Figures 3B, C). The increased
frequencies in these T-cell subsets was transient, as it was not
observed at a later time point (i.e. day 8) (Supplementary Tables
1 and 2). At day 8 post cryoablation, naive CD8+ T-cell
frequencies in the TDLN were significantly increased in both
slow and fast freeze groups (Figure 3D). Interestingly, at 8 days
post cryoablation, frequencies of CD4+ conventional T-cells and
their proliferation status were significantly increased in both the
TDLN and the contralateral tumor non-draining lymph node
(TNDLN) only in the fast freeze group (Figures 3E, F and
Supplementary Tables 2, 4), indicative of systemic immuneFIGURE 1 | Survival of melanoma bearing mice treated with cryoablation at
slow freeze or fast freeze rates. Mice were transplanted with 5 x 106 B16F10
melanoma cells sub-cutaneously on day 1 and received cryoablation between
days 7-9. Kaplan-Meier survival curves of mice treated with slow freeze or fast
freeze, along with non-treated controls. Data obtained from four independent
experiments. Non-treated controls (n = 18), slow freeze (n = 35), fast freeze
(n = 34). Numbers displayed on the graph indicate the no. of tumor-free
surviving mice/total no. of mice employed for each group. Survival curves were
analyzed using log-rank (Mantel-Cox) test. *P < 0.05, ****P < 0.0001.June 2021 | Volume 12 | Article 695150
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PD1+ CD4+ Tregs at day 8 post ablation in TDLN in both slow
and fast freeze groups (P=0.076 and P=0.082, respectively
Supplementary Table 2).
Interestingly, we also observed increased frequencies of
migratory and conventional (resident) dendritic cell subsets in
both fast and slow freeze groups vs non-treated controls, in the
TNDLN at day 8 post treatment (Supplementary Table 4). No
difference in DCs frequencies was found between both
cryoablation groups and controls in TDLN. This could be due
to the fact that the tumor bearing control mice had a high
percentage of DCs in the local TDLN due to the presence of a
growing tumor and its associated inflammation. As a result, we
did not observe a further increase in DCs in TDLN post
cryoablation when compared to controls.
Collectively, these results indicate that cryoablation
(irrespective of the protocol) was able to initiate local immune
responses as shown by increased frequencies of CD8+ T-cells in
TDLN at day 8 post treatment. However, the conventional CD4+
conventional T-cells (non-Tregs) were increased only in the fast
freeze group, both in the local TDLN and distant TNDLN,
suggestive of systemic immune responses. This indicates that
fast freeze could be advantageous over slow freeze in eliciting
immune responses.Frontiers in Immunology | www.frontiersin.org 5Myeloid Cells Infiltrate the Tumors Early
After Cryoablation
We also examined for changes in the myeloid cell composition in
tumors post cryoablation (Figure 4A). Neutrophils, known as the
primary responders of infection and injury (14), were increased at
day 3-4 and 8 post cryoablation in both treatment groups
(Figures 4B, C). Intriguingly, at day 8 post ablation, eosinophils
were significantly increased in the fast freeze group, and exhibited
an increasing trend in the slow freeze group (Figure 4D).
Frequencies of other cell types such as DCs either decreased (in
particular in the first days following ablation, reflecting treatment-
related cell death) or remained unchanged such as monocytes and
macrophages (Supplementary Tables 5 and 6).
Cryoablation With Fast Freeze Rate
Improves Survival Post Re-Challenge
In order to investigate the systemic immunological impact of
cryoablation, splenocytes at 8 days post ablation were stimulated
in vitro with PMA and ionomycin. Frequencies of IFN-g
expressing CD4+, and TNF-a expressing CD4+ and CD8+
T-cells were significantly higher in fast freeze group as
compared to non-treated controls. An increasing trend was also
observed in the slow freeze group in comparison to non-treated
controls. No differences were observed between the groups in theA
B
FIGURE 2 | Impact of differential freeze rate on tumor necrosis. (A) Representative images of H&E staining of tumor tissue sections obtained at 8 days post
cryoablation, along with non-treated tumor controls. Images acquired at 10X magnification. Arrowheads indicate necrotic tissue, and asterisks indicate viable tumor.
Scale represents 1000µm. (B) Quantification of tumor necrosis in non-treated and cryoablated tumor tissues. Data plotted as mean and ± S.D. obtained from two
independent experiments (n = 7-14). Data was analyzed using non-parametric Mann-Whitney U test. *P < 0.05, ****P < 0.0001.June 2021 | Volume 12 | Article 695150
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Tetramer staining of splenocytes for the detection of Gp-100
and Trp-2 antigen specific CD8+ T-cells did not reveal any
significant differences between the non-treated and the
cryoablated groups. Similar results were also obtained from IFN-Frontiers in Immunology | www.frontiersin.org 6g elispot assay of splenic CD8+ T-cells with Trp-2 antigen
(Supplementary Figure 3). In addition, we also did not observe
any significant increase in the systemic levels of investigated
plasma cytokines at day 3 or day 8 post cryoablation in





FIGURE 3 | Cryoablation-induced changes in the immune cell compartments in local tumor draining lymph node (TDLN) and distant contralateral tumor non-draining
lymph node (TNDLN). (A) Flow cytometry gating strategies employed to characterize CD4+ and CD8+ T-cell subsets. (B, C) Percentages of CD8+ central memory T-
cells and CD4+ regulatory T-cells (Tregs) within live cells in TDLN at day 3-4 post cryoablation. (D, E) Percentages of CD8+ naive T-cells and CD4+ conventional
(Conv.) T-cells within live cells in TDLN at day 8 post cryoablation. (F) Percentages of CD4+ Conv. T-cells within live cells in TNDLN at day 8 post cryoablation. Data
plotted as mean and ± S.D. obtained from four independent experiments (n = 6-16). Each data point represents an individual mouse. Data was analyzed using non-
parametric Mann-Whitney U test. *P < 0.05, NS, not significant.June 2021 | Volume 12 | Article 695150
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remained tumor-free for at least 2 months from the time of initial
B16F10 transplant were re-challenged with the same cells on their
contralateral flank. Significantly more mice treated with the fast
freeze reached this point than the ones treated with the slow freezeFrontiers in Immunology | www.frontiersin.org 7protocol (15 vs 6mice), and were subsequently used for re-challenge
experiments. In comparison to the naïve mice that received
melanoma cells for the first time, re-challenged mice only from
the fast freeze group survived significantly longer [median overall




FIGURE 4 | Cryoablation-induced changes in the tumor infiltrating myeloid cells. (A) Flow cytometry gating strategies employed to characterize tumor infiltrating
myeloid cells. (B, C) Percentages of neutrophils within live cells at days 3-4 and 8 post cryoablation. (D) Percentages of eosinophils within live cells at day 8 post
cryoablation. Data plotted as mean and ± S.D. obtained from four independent experiments (n = 7-16). Each data point represents an individual mouse. Data was
analyzed using non-parametric Mann-Whitney U test. **P < 0.01, ***P < 0.001. NS, not significant.June 2021 | Volume 12 | Article 695150
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immunological memory responses against tumors, that restricted
the tumor growth and extended the survival post re-challenge.DISCUSSION
The main finding of this study is that cryoablation with fast
freeze protocol achieved strong anticancer effects locoregionallyFrontiers in Immunology | www.frontiersin.org 8in the treated tumor with enhanced survival in a mouse model of
melanoma. Moreover, our data obtained from a combination of
ex vivo immune cell characterization and in vivo re-challenge
experiments demonstrates favorable systemic immunogenic
properties of the fast freeze rate.
Rate of freeze is a critical parameter of the local effectiveness
of cryoablation. Fast freeze protocols achieve higher levels of
intracellular ice formation with greater causation of tissue




FIGURE 5 | Cryoablation by fast freeze rate induces immune responses and extends the survival post re-challenge. (A–D) Spleens isolated at day 7-8 post
cryoablation, along with non-treated controls. Splenocytes stimulated in vitro for 6 hours with PMA and ionomycin. (A, B) Percentages of interferon-g+ and tumor
necrosis factor-a+ cells within total CD4+ T-cell fraction. (C, D) Percentages of interferon-g+ and tumor necrosis factor-a+ cells within total CD8+ T-cell fraction. Data
plotted as mean and ± S.D. obtained from three independent experiments (n=8-10). (E) Cryoblation-treated tumor-free surviving mice were subjected to re-challenge
with 5 x 106 B16F10 cells on the contralateral flank between 60-70 days post primary melanoma cell transplant. Kaplan-Meier survival curves of mice post re-
challenge, which previously received fast freeze (n=15) or slow freeze (n=6) ablation treatments, along with naive mice (n=8) that received melanoma cells for the first
time. Data plotted was obtained from three independent experiments, and analyzed using log-rank (Mantel-Cox) test. *P < 0.05, **P < 0.01, NS, not significant.June 2021 | Volume 12 | Article 695150
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was observed. However, when cryoablation is to be used as an in
vivo vaccination tool, the variation in the mechanistic processes
of fast and slow freeze rates on cell injury may influence the
balance of necrosis/apoptosis, and the quality of the immune
responses (11, 12, 15). There are reports indicating that tumor
necrosis elicits immunogenic responses (16, 17), whereas some
contradicting studies suggest that apoptosis (as opposed to
necrosis) is a strong driver of anti-tumor immune responses
(18, 19). A previous study by Sabel et al. reported the advantage
of fast freeze over slow freeze, but information regarding
necrosis/apoptosis in the ablated tissue, and an in-depth
characterization of immune responses appear lacking (11). Our
study focused on addressing these aspects with an aim of
choosing the right protocol that would augment the impact of
targeted immunotherapies employed in combination with
cryoablation in clinical settings.
We first tested the impact of fast and slow freeze in their
ability to eradicate the tumor locally. Our results demonstrated
that fast freeze protocol ablated the tumor effectively and
improved the survival as compared to slow freeze, confirming
previously observed results in a breast cancer model (11). As a
next step, we determined the extent of apoptosis and necrosis
induced in the tumor by slow and fast freeze protocols. On day 8
post ablation, we did not observe any treatment-induced
apoptosis, even at the periphery of the ablation zone, which
has been suggested to undergo apoptosis (15). Our data suggests
that the cryoablated tumor tissue predominantly dies by necrosis,
with rapid freeze rate inducing a greater extent of tissue necrosis
than slow freeze rate. The presence of remaining viable tumor
tissue in the slow freeze group is likely to have resulted in tumor
re-growth post ablation, and therefore, a significantly reduced
survival as compared to the fast freeze group.
In order to see if the difference in the extent of necrosis
observed between fast and slow freeze is associated with a
variation in the degree of immune responses, we studied the
immune cell composition in local TDLN, distant contralateral
TNDLN, and tumors, post ablation. At day 3-4 post treatment,
fast freeze mode of ablation resulted in a transient increase of
CD8+ central memory T-cell proportions in TDLN, in
comparison to slow freeze and non-treated control groups. In
fact, this brief time window seems not enough for the generation
of memory responses. It can be explained by the presence of an
already existing memory T-cell repertoire specific to tumor-
associated melanoma antigens. In line with our data, a recent
study on healthy human blood samples revealed the presence of a
low affinity CD8+ T-cell pool specific to melanoma antigens,
referred to as natural autoreactive T-cells. The behavior exhibited
by these T-cells upon melanoma antigen stimulation ex-vivo
implied that they belong to the central memory pool of T-cells
(20). Cryoablation with fast freeze could have led to the increased
frequency of these pre-existing memory cells, due to the
increased availability of tumor antigens. We have also observed
a concomitant increase in Tregs in the fast freeze group, which
could indicate an immunoregulatory mechanism in place to
counteract the autoreactive CD8+ T-cells. These results mayFrontiers in Immunology | www.frontiersin.org 9also encourage the application of anti-CTLA4 therapy that
could selectively deplete the Tregs (21), and upon co-
application with cryoablation is likely to result in an improved
anti-tumor immunity, as demonstrated previously (22, 23). Both
the modes of cryoablation resulted in increased frequencies of
naïve CD8+ T-cells in TDLNs at day 8 post treatment. This was
also accompanied in the fast freeze group by an increased
frequency of CD4+ T-cells and their proliferative status, both
in TDLN and TNDLN, indicative of local and systemic immune
responses. In the distant contralateral TNDLN, the percentage of
DC subsets was increased in both cryoablation groups as
compared to controls. These results suggest that fast freeze
evokes relatively stronger immune responses in comparison to
slow freeze, both at local and systemic levels.
Increased proportion of neutrophils was observed in the
tumor immune infiltrate at both time points post cryoablation,
as neutrophils are known to be the initial entrants to the site of
injury. Data from a recent study suggests that neutrophils are
rapidly mobilized from the bone marrow to the ablated site, as
demonstrated by a drop of neutrophils in the bone marrow and a
corresponding spike in the peripheral blood by 24hrs post
ablation (24). In addition, we also observed an increased
frequency of eosinophils in the tumors at day 8 post ablation.
Tumor infiltrating eosinophils are known to secrete cytokines
and chemokines to attract T-cells for combating the tumors (25).
Indeed, eosinophil infiltration into tumors has been shown to
positively correlate with patient survival in many cancers
including melanoma (26). Future studies should investigate if
cryoablation of a tumor triggers eosinophil infiltration in distant,
non-treated tumor sites.
Increased frequencies of TNF-a and IFN-g producing CD4+ T-
cells and TNF-a producing CD8+ T-cells were observed in the fast
freeze group when compared to non-treated controls, when the
splenocytes were in vitro stimulated with PMA and ionomycin. An
increasing trend was also observed in the slow freeze group. These
results suggest that the splenic T-cells from the cryoablated mice
were immunologically activated due to ablation, and therefore, had
a higher percentage of TNF-a and IFN-g producing T-cells upon in
vitro stimulation. This data further underscores the induction of
systemic immunity as a result of cryoablation, in particular, with the
fast freeze protocol. Intriguingly, we neither observed a systemic
increase of Gp-100 or Trp-2 antigen specific CD8+ T-cells nor an
increased production of IFN-g by splenic CD8+ T-cells stimulated
with a Trp-2 antigen in vitro. This could indicate that Gp-100 and
Trp-2 tumor-associated antigens might not have an important role
to play in the induction of systemic immunity post cryoablation. An
alternative explanation could be that the frequencies of Gp-100 and
Trp-2 antigen specific T-cells are too low to be detected in our
experimental system. We also did not observe any significant
increase in the systemic levels of plasma cytokines post cryoablation.
As a last step, we re-challenged the tumor-free surviving mice
post cryoablation with a high dose of 5 x 106 B16F10 melanoma
cells in the opposite flank. As compared to naive mice,
significantly improved survival was only observed in the group
that was prior treated with the fast freeze protocol, but not with
the slow freeze protocol. This also corroborates the differences inJune 2021 | Volume 12 | Article 695150
Yakkala et al. Freeze Rate Influences Immune Responsesthe observed immune responses between the fast and slow freeze
treatments. In a similar previous study with B16OVA tumors, re-
challenge of tumor-free mice that were prior treated with
cryoablation resulted in 40-50% long-term survivors that
completely rejected the tumor (22). In our study, all the re-
challenged mice of the fast freeze group died at a later time point,
without any long-term survivors. The difference in the outcomes
could be due to the fact that the previous study employed
B16OVA cell line, which is more immunogenic than the
B16F10 cell line employed in our study. More importantly, re-
challenge was performed with 15 x 103 cells in the previous study
as compared to 5 x 106 cells used in our study, indicating that the
ability to completely reject the tumor cells in a re-challenge
experiment also varies with the number of cells implanted.
In conclusion, cryoablation with fast freeze rate should be
preferred over slow freeze rate owing to the locoregional tumor
control and the associated immune responses. Therefore,
cryoablation with a fast freeze rate should be applied in future
for the combinatorial application of cryoablation with
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Supplementary Figure 1 | Tumor growth kinetics of melanoma bearing mice
treated with cryoablation at slow freeze or fast freeze rates. Mice were transplanted
with 5 x 106 B16F10 melanoma cells sub-cutaneously on day 1 and received
cryoablation between days 7-9. Tumor growth curves of each individual mouse
from (A) non-treated (n=18), (B) slow freeze (n=35), and (C) fast freeze (n=34)
groups. Data pooled from four independent experiments.
Supplementary Figure 2 | Cryoablation does not induce apoptosis. Cleaved
caspase-3 staining of tumor tissue sections obtained from (A) non-treated controls,
and 8 days post (B) slow freeze or (C) fast freeze treatment protocols. Images
acquired at 10X magnification. Arrowheads indicate cleaved-caspase-3 positive
cells, and asterisks indicate the limiting plate between viable and necrotic tissue.
Scale represents 1000µm. Representative data obtained from two independent
experiments (n=7-14).
Supplementary Figure 3 | Immune responses against Gp-100 and Trp-2
antigens post cryoablation. Spleens isolated from non-treated controls and at day
7-8 post cryoablation. Percentages of (A) Gp-100 specific and (B) Trp-2 specific T-
cells within the total CD8+ T-cell fraction. (C) Elispot-based quantification of
interferon-g production by splenic CD8+ T-cells incubated in vitro with murine Trp-2
(SVYDFFVWL) antigen. Representative data obtained from three independent
experiments (n=8-11). NS, not significant.
Supplementary Figure 4 | Tumor growth kinetics post re-challenge.
Cryoblation-treated, tumor-free, long-term surviving mice were subjected to re-
challenge with 5 x 106 B16F10 cells on the contralateral flank between 60-70 days
post primary B16F10 cell transplant. Tumor growth curves of each individual mouse
from (A) Naive control mice that received melanoma cells for the first time (n=8); re-
challenged mice from (B) slow freeze (n=6), and (C) fast freeze (n=15) groups. Data
pooled from three independent experiments.
Supplementary Table 1 | Differences in percentages of immune cell populations
between experimental groups at day 3-4 post cryoablation in tumor draining lymph
node (TDLN). Data was analyzed using non-parametric Mann-Whitney U test. NS, not
significant. Higher (↑) or lower (↓) post cryoablation than non-treated controls (columns
1 and 2). Higher (↑) or lower (↓) post fast freeze than slow freeze group (column 3).
Supplementary Table 2 | Differences in percentages of immune cell populations
between experimental groups at day 8 post cryoablation in tumor draining lymph
node (TDLN). Data was analyzed using non-parametric Mann-Whitney U test. NS, not
significant. Higher (↑) or lower (↓) post cryoablation than non-treated controls (columns
1 and 2). Higher (↑) or lower (↓) post fast freeze than slow freeze group (column 3).
Supplementary Table 3 | Differences in percentages of immune cell populations
between experimental groups at day 3-4 post cryoablation in tumor non-draining
lymph node (TNDLN). Data was analyzed using non-parametric Mann-Whitney U
test. NS, not significant. Higher (↑) or lower (↓) post ablation than non-treated
controls (columns 1 and 2). Higher (↑) or lower (↓) post fast freeze than slow freeze
group (column 3).
Supplementary Table 4 | Differences in percentages of immune cell populations
between experimental groups at day 8 post cryoablation in tumor non-draining
lymph node (TNDLN). Data was analyzed using non-parametric Mann-Whitney U
test. NS, not significant. Higher (↑) or lower (↓) post cryoablation than non-treated
controls (columns 1 and 2). Higher (↑) or lower (↓) post fast freeze than slow freeze
group (column 3).June 2021 | Volume 12 | Article 695150
Yakkala et al. Freeze Rate Influences Immune ResponsesSupplementary Table 5 | Differences in percentages of immune cell populations
between experimental groups at day 3-4 post cryoablation in tumors. Data was
analyzed using non-parametric Mann-Whitney U test. NS, not significant. Higher (↑)
or lower (↓) post cryoablation than non-treated controls (columns 1 and 2). Higher
(↑) or lower (↓) post fast freeze than slow freeze group (column 3).Frontiers in Immunology | www.frontiersin.org 11Supplementary Table 6 | Differences in percentages of immune cell populations
between experimental groups at day 8 post cryoablation in tumors. Data was
analyzed using non-parametric Mann-Whitney U test. NS, not significant. Higher (↑)
or lower (↓) post cryoablation than non-treated controls (columns 1 and 2). Higher
(↑) or lower (↓) post fast freeze than slow freeze group (column 3).REFERENCES
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